IDEXX Laboratories, Inc. vs New York Times Co — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.8× New York Times Co's market cap, and New York Times Co pays a 1.38% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and New York Times Co for 81 Days on average.
| IDXX | NYT | |
|---|---|---|
Market Cap | $40.43B | $10.74B |
Volume | 692,164 | 2,096,352 |
Sector | Health | Media |
52-Week High | $766.68 | $85.86 |
52-Week Low | $504.70 | $54.66 |
Typical Hold Time | 46 Days | 81 Days |
Enterprise Value | $41.32B | $10.14B |
Dividend Yield | — | 1.38% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
The New York Times Company (NYT) trades at $66.32, up 2.19% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. The stock shows a bullish technical signal with key support at $65-66 and resistance at $67-68, while maintaining robust profitability with 51.41% gross margins and 13.19% net income margin. Recent developments include a declared $0.23 dividend and ongoing AI copyright litigation.
Outlook remains positive with analyst consensus target of $84 representing 27% upside potential, though risks include the shareholder lawsuit alleging bias and competitive pressures in digital media. The company's strong cash flow generation and dividend payments provide shareholder value, while earnings growth trajectory supports continued valuation expansion if execution remains solid.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →